E-cigarette battle lines form in federal court

Last week, we highlighted the Oregon attorney general's fight against e-cigarettes, which he considers to be a drug-delivery device being sold to consumers without proper approval from the FDA. The Wall Street Journal points out that the battle goes far beyond Oregon. It is nationwide and just beginning. The industry that markets the battery-powered tubes that turn nicotine-laced liquid into into vapor claims that it is offering products "designed to be recreational alternatives to cigarettes, not devices to wean people off nicotine." If they had to go through clinical trials, they'd be out of business or forced underground. Next week, a federal appellate court hears oral arguments on the question. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.